Verifying…
Home / Drug A–Z / Androgel 16.2 mg/g (Testosterone Gel)

Androgel 16.2 mg/g (Testosterone Gel)

NAFDAC Reg. No. C4-1623 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Androgel 16.2 mg/g (Testosterone Gel)
NAFDAC number
C4-1623
Active ingredient
Testosterone
Strength
16.2 mg/g
Form
Gel
Pack size
88 g x 1's
Manufacturer
Not listed
Applicant (holder)
Assene-Laborex Limited
Approved
25 Feb 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
24 Feb 2026
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Androgel 16.2 mg/g (Testosterone Gel) is on the NAFDAC register with an active registration (C4-1623). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Androgel 16.2 mg/g (Testosterone Gel)

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. …

How to take it and how often
  • Prior to initiating, TESTOPEL ® (testosterone pellets) confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range
  • The suggested dosage for androgens varies depending on the age, and diagnosis of the individual patient
  • Dosage is adjusted according to the patient’s response and the appearance of adverse reactions
  • The dosage guideline for the testosterone pellets for replacement therapy in androgen-deficient males is 150mg to 450mg subcutaneously every 3 to 6 months
  • Various dosage regimens have been used to induce pubertal changes in hypogonadal males; some experts have advocated lower doses initially, gradually increasing the dose as puberty progresses, with or without a decrease in maintenance levels
  • Other experts emphasize that higher dosages are needed to induce pubertal changes and lower dosages can be used for maintenance after puberty
  • The chronological and skeletal ages must be taken into consideration, both in determining the initial dose and in adjusting the dose
  • Dosages in delayed puberty generally are in the lower range of that listed above and, for a limited duration, for example 4 to 6 months
  • The number of pellets to be implanted depends upon the minimal daily requirements of testosterone propionate determined by a gradual reduction of the amount administered parenterally
  • The usual dosage is as follows: implant two 75mg pellets for each 25mg testosterone propionate required weekly. …
Talk to a doctor first if
  • Androgens are contraindicated in men with carcinomas of the breast or with known or suspected carcinomas of the prostate
  • If administered to pregnant women, androgens cause virilization of the external genitalia of the female fetus
  • The virilization includes clitoromegaly, abnormal vaginal development, and fusion of genital folds to form a scrotal-like structure. …
Warnings

In patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis. In this case, the drug should be discontinued. Prolonged use of high doses of androgens has been associated with the development of peliosis hepatis and hepatic neoplasms including hepatocellular carcinoma (see PRECAUTIONS - Carcinogenesis, Mutagenesis, Impairment of Fertility). Peliosis hepatis can be a life-threatening or fatal complication. Men treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma. …

Possible side effects

The following adverse reactions have been identified during post-approval use of testosterone replacement therapy, including TESTOPEL ® . Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Implantation Site Infection and Pellet Extrusion: (see WARNINGS) Endocrine and Urogenital, Male. Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high dosages (see CLINICAL PHARMACOLOGY ). Skin and Appendages. Hirsutism, male pattern of baldness, and acne. Cardiovascular Disorders. …

If you take too much

There have been no reports of acute overdosage with the androgens.

Dependence and misuse

Controlled Substance TESTOPEL ® contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. Abuse Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2025-07-17.

Label for testosterone, the active ingredient registered with NAFDAC.

Check your pack of Androgel 16.2 mg/g (Testosterone Gel)

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC · WHO · U.S. FDA · Health Canada · NLM

About Androgel 16.2 mg/g (Testosterone Gel)

What is in Androgel 16.2 mg/g (Testosterone Gel)?

Androgel 16.2 mg/g (Testosterone Gel) contains Testosterone (16.2 mg/g), as gel, according to its NAFDAC registration record.

Is Androgel 16.2 mg/g (Testosterone Gel) registered with NAFDAC?

Yes. Androgel 16.2 mg/g (Testosterone Gel) is listed on the NAFDAC register under registration number C4-1623, and its registration is active as of 28 October 2026.

Has Androgel 16.2 mg/g (Testosterone Gel) been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Androgel 16.2 mg/g (Testosterone Gel) in our automatically synced alert list.

How can I check that my pack of Androgel 16.2 mg/g (Testosterone Gel) is genuine?

Run a free authenticity scan with the NAFDAC number C4-1623, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Androgel 16.2 mg/g (Testosterone Gel)?

Follow your prescription or the leaflet in your pack. The official label says: Prior to initiating, TESTOPEL ® (testosterone pellets) confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these serum testosterone concentrations are below the normal range. The suggested dosage for androgens varies depending on the age, and diagnosis of the individual…

What is Androgel 16.2 mg/g (Testosterone Gel) used for?

MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropic LHRH deficiency, or pituit (Summarised from the official U.S. FDA label for testosterone. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Androgel 16.2 mg/g (Testosterone Gel)? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.